| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Heart Failure | 416 | 2024 | 11836 | 27.330 |
Why?
|
| Stroke Volume | 235 | 2024 | 5513 | 13.970 |
Why?
|
| Angiotensin Receptor Antagonists | 67 | 2024 | 1025 | 9.110 |
Why?
|
| Tetrazoles | 44 | 2024 | 901 | 5.980 |
Why?
|
| Biphenyl Compounds | 45 | 2024 | 988 | 5.800 |
Why?
|
| Diabetes Mellitus, Type 2 | 83 | 2024 | 12280 | 5.660 |
Why?
|
| Hospitalization | 118 | 2024 | 10761 | 5.010 |
Why?
|
| Cardiovascular Diseases | 74 | 2024 | 15739 | 4.930 |
Why?
|
| Drug Combinations | 43 | 2024 | 2024 | 4.910 |
Why?
|
| Ventricular Function, Left | 76 | 2024 | 3871 | 4.590 |
Why?
|
| Renal Insufficiency, Chronic | 33 | 2024 | 2296 | 4.270 |
Why?
|
| Benzhydryl Compounds | 38 | 2024 | 942 | 4.130 |
Why?
|
| Ventricular Dysfunction, Left | 29 | 2024 | 2130 | 3.980 |
Why?
|
| Glucosides | 29 | 2024 | 536 | 3.820 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 38 | 2024 | 1521 | 3.520 |
Why?
|
| Glomerular Filtration Rate | 27 | 2024 | 2178 | 3.210 |
Why?
|
| Hypoglycemic Agents | 32 | 2024 | 3149 | 2.920 |
Why?
|
| Adenosine Monophosphate | 9 | 2019 | 283 | 2.900 |
Why?
|
| Humans | 660 | 2024 | 760276 | 2.670 |
Why?
|
| Diuretics | 17 | 2024 | 612 | 2.620 |
Why?
|
| Clinical Trials as Topic | 40 | 2024 | 8058 | 2.590 |
Why?
|
| Ticlopidine | 14 | 2017 | 895 | 2.580 |
Why?
|
| Platelet Aggregation Inhibitors | 26 | 2021 | 3202 | 2.500 |
Why?
|
| Diabetes Mellitus | 25 | 2023 | 5884 | 2.440 |
Why?
|
| Myocardial Infarction | 44 | 2024 | 11894 | 2.370 |
Why?
|
| Cardiology | 15 | 2024 | 1723 | 2.190 |
Why?
|
| Spironolactone | 11 | 2024 | 411 | 2.090 |
Why?
|
| Benzazepines | 14 | 2019 | 311 | 2.020 |
Why?
|
| Natriuretic Peptides | 16 | 2024 | 156 | 2.010 |
Why?
|
| Cardiovascular Agents | 14 | 2022 | 865 | 1.940 |
Why?
|
| Neprilysin | 16 | 2024 | 472 | 1.930 |
Why?
|
| Natriuretic Peptide, Brain | 31 | 2024 | 1705 | 1.880 |
Why?
|
| Aged | 228 | 2024 | 169002 | 1.820 |
Why?
|
| Renin-Angiotensin System | 14 | 2024 | 739 | 1.820 |
Why?
|
| Patient Readmission | 28 | 2024 | 3329 | 1.820 |
Why?
|
| Proton Pump Inhibitors | 5 | 2016 | 551 | 1.800 |
Why?
|
| Registries | 34 | 2024 | 8450 | 1.780 |
Why?
|
| United States Food and Drug Administration | 11 | 2021 | 1675 | 1.760 |
Why?
|
| Coronavirus Infections | 10 | 2020 | 3086 | 1.750 |
Why?
|
| Acute Coronary Syndrome | 17 | 2024 | 2363 | 1.730 |
Why?
|
| Pneumonia, Viral | 10 | 2020 | 3206 | 1.730 |
Why?
|
| Aspirin | 16 | 2021 | 3365 | 1.640 |
Why?
|
| Atrial Flutter | 6 | 2022 | 258 | 1.600 |
Why?
|
| United States | 120 | 2024 | 72369 | 1.560 |
Why?
|
| Adrenergic beta-Antagonists | 11 | 2023 | 1256 | 1.540 |
Why?
|
| Inpatients | 14 | 2023 | 2580 | 1.540 |
Why?
|
| Naphthyridines | 4 | 2024 | 141 | 1.520 |
Why?
|
| Treatment Outcome | 109 | 2024 | 64968 | 1.510 |
Why?
|
| Foramen Ovale, Patent | 3 | 2018 | 214 | 1.500 |
Why?
|
| Randomized Controlled Trials as Topic | 45 | 2024 | 10343 | 1.500 |
Why?
|
| Male | 272 | 2024 | 359427 | 1.500 |
Why?
|
| Atrial Fibrillation | 23 | 2023 | 5202 | 1.490 |
Why?
|
| Cardiotonic Agents | 11 | 2020 | 546 | 1.480 |
Why?
|
| Death, Sudden, Cardiac | 6 | 2021 | 1572 | 1.480 |
Why?
|
| Antihypertensive Agents | 18 | 2023 | 2063 | 1.420 |
Why?
|
| Female | 270 | 2024 | 391024 | 1.410 |
Why?
|
| Metabolic Diseases | 3 | 2022 | 686 | 1.410 |
Why?
|
| Purinergic P2Y Receptor Antagonists | 8 | 2019 | 380 | 1.380 |
Why?
|
| Defibrillators, Implantable | 8 | 2022 | 1499 | 1.360 |
Why?
|
| Drug Utilization | 8 | 2021 | 1195 | 1.340 |
Why?
|
| Middle Aged | 185 | 2024 | 220179 | 1.330 |
Why?
|
| Disease Management | 13 | 2024 | 2508 | 1.280 |
Why?
|
| Coronary Thrombosis | 5 | 2016 | 486 | 1.280 |
Why?
|
| Angioedema | 2 | 2020 | 192 | 1.270 |
Why?
|
| Patient Selection | 17 | 2024 | 4276 | 1.250 |
Why?
|
| Medicare | 25 | 2024 | 6771 | 1.230 |
Why?
|
| Hypertension | 18 | 2023 | 8595 | 1.220 |
Why?
|
| Kidney | 22 | 2024 | 7071 | 1.220 |
Why?
|
| Pandemics | 17 | 2023 | 8621 | 1.190 |
Why?
|
| Diabetic Nephropathies | 3 | 2023 | 988 | 1.190 |
Why?
|
| Drug Labeling | 2 | 2021 | 251 | 1.190 |
Why?
|
| Double-Blind Method | 37 | 2024 | 12412 | 1.180 |
Why?
|
| Anticoagulants | 16 | 2023 | 4899 | 1.170 |
Why?
|
| Practice Guidelines as Topic | 14 | 2024 | 7469 | 1.140 |
Why?
|
| Angiotensins | 8 | 2024 | 143 | 1.130 |
Why?
|
| Specialization | 3 | 2021 | 779 | 1.130 |
Why?
|
| Prognosis | 83 | 2024 | 29640 | 1.130 |
Why?
|
| Digoxin | 6 | 2022 | 247 | 1.100 |
Why?
|
| Platelet Aggregation | 6 | 2016 | 805 | 1.080 |
Why?
|
| Blood Pressure | 22 | 2023 | 8523 | 1.050 |
Why?
|
| Influenza Vaccines | 8 | 2024 | 770 | 1.040 |
Why?
|
| Glucagon-Like Peptides | 2 | 2024 | 159 | 1.020 |
Why?
|
| Cause of Death | 18 | 2024 | 3723 | 1.020 |
Why?
|
| Patient Discharge | 21 | 2023 | 3476 | 1.020 |
Why?
|
| Omeprazole | 2 | 2016 | 112 | 1.020 |
Why?
|
| Hypotension | 7 | 2024 | 883 | 1.010 |
Why?
|
| Coronary Artery Disease | 14 | 2022 | 6662 | 1.010 |
Why?
|
| Troponin T | 8 | 2023 | 774 | 1.000 |
Why?
|
| Dipeptidyl-Peptidase IV Inhibitors | 3 | 2020 | 334 | 0.990 |
Why?
|
| Receptors, Purinergic P2Y12 | 2 | 2016 | 124 | 0.990 |
Why?
|
| Risk Assessment | 43 | 2024 | 24086 | 0.990 |
Why?
|
| Renal Insufficiency | 7 | 2019 | 820 | 0.940 |
Why?
|
| Gastrointestinal Hemorrhage | 5 | 2024 | 1130 | 0.940 |
Why?
|
| Heart Diseases | 6 | 2023 | 2810 | 0.930 |
Why?
|
| Heart Transplantation | 7 | 2023 | 3217 | 0.930 |
Why?
|
| Symporters | 3 | 2022 | 361 | 0.930 |
Why?
|
| Risk Factors | 79 | 2024 | 74278 | 0.930 |
Why?
|
| Metformin | 2 | 2023 | 912 | 0.920 |
Why?
|
| Drug Approval | 5 | 2021 | 816 | 0.920 |
Why?
|
| Blood Platelets | 9 | 2016 | 2522 | 0.910 |
Why?
|
| Atherosclerosis | 13 | 2023 | 3524 | 0.900 |
Why?
|
| Hospitals | 9 | 2021 | 3930 | 0.880 |
Why?
|
| Shock, Cardiogenic | 3 | 2019 | 736 | 0.880 |
Why?
|
| Stroke | 16 | 2023 | 9946 | 0.880 |
Why?
|
| Peptide Fragments | 21 | 2024 | 5120 | 0.880 |
Why?
|
| Ventricular Dysfunction, Right | 3 | 2023 | 615 | 0.870 |
Why?
|
| Heart Valve Prosthesis Implantation | 4 | 2023 | 1584 | 0.870 |
Why?
|
| Drug Therapy, Combination | 16 | 2024 | 6499 | 0.850 |
Why?
|
| Information Dissemination | 4 | 2021 | 1132 | 0.840 |
Why?
|
| Death, Sudden | 4 | 2022 | 302 | 0.840 |
Why?
|
| Research Design | 13 | 2023 | 6181 | 0.830 |
Why?
|
| Aged, 80 and over | 64 | 2024 | 58953 | 0.830 |
Why?
|
| International Classification of Diseases | 5 | 2021 | 884 | 0.820 |
Why?
|
| Mitral Valve Insufficiency | 5 | 2023 | 1420 | 0.820 |
Why?
|
| Hospital Mortality | 28 | 2022 | 5422 | 0.810 |
Why?
|
| Influenza, Human | 8 | 2024 | 1532 | 0.800 |
Why?
|
| Pharmacy | 1 | 2023 | 92 | 0.800 |
Why?
|
| Albuminuria | 4 | 2023 | 659 | 0.790 |
Why?
|
| Heart Failure, Diastolic | 5 | 2024 | 77 | 0.790 |
Why?
|
| Pharmacies | 1 | 2023 | 164 | 0.780 |
Why?
|
| Sodium | 13 | 2023 | 1601 | 0.780 |
Why?
|
| Drug-Eluting Stents | 5 | 2017 | 759 | 0.770 |
Why?
|
| Time Factors | 41 | 2024 | 40141 | 0.760 |
Why?
|
| Angiotensin II Type 1 Receptor Blockers | 4 | 2024 | 435 | 0.760 |
Why?
|
| Kidney Diseases | 2 | 2023 | 2093 | 0.750 |
Why?
|
| Drug Prescriptions | 3 | 2020 | 1673 | 0.750 |
Why?
|
| Fumarates | 3 | 2018 | 131 | 0.750 |
Why?
|
| Comorbidity | 28 | 2024 | 10553 | 0.730 |
Why?
|
| Follow-Up Studies | 41 | 2024 | 39256 | 0.730 |
Why?
|
| Health Status | 7 | 2023 | 4084 | 0.730 |
Why?
|
| Angioplasty, Balloon, Coronary | 4 | 2017 | 1880 | 0.720 |
Why?
|
| Anterior Wall Myocardial Infarction | 2 | 2021 | 44 | 0.710 |
Why?
|
| Medicaid | 8 | 2021 | 2811 | 0.700 |
Why?
|
| Hyperkalemia | 2 | 2022 | 231 | 0.700 |
Why?
|
| Endpoint Determination | 7 | 2022 | 597 | 0.700 |
Why?
|
| Amides | 4 | 2021 | 448 | 0.690 |
Why?
|
| Heart-Assist Devices | 5 | 2022 | 1292 | 0.690 |
Why?
|
| Cardiomyopathies | 5 | 2024 | 1946 | 0.690 |
Why?
|
| Blood Pressure Determination | 3 | 2020 | 641 | 0.680 |
Why?
|
| Renin | 2 | 2021 | 636 | 0.670 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 8 | 2021 | 3333 | 0.660 |
Why?
|
| Medicare Part D | 5 | 2021 | 354 | 0.640 |
Why?
|
| Iliac Artery | 1 | 2020 | 344 | 0.640 |
Why?
|
| Blood Glucose | 10 | 2024 | 6375 | 0.630 |
Why?
|
| Epirubicin | 1 | 2018 | 83 | 0.630 |
Why?
|
| Economics, Hospital | 4 | 2020 | 212 | 0.630 |
Why?
|
| Troponin | 3 | 2017 | 516 | 0.630 |
Why?
|
| Cardiovascular System | 3 | 2022 | 850 | 0.620 |
Why?
|
| Stents | 5 | 2017 | 3306 | 0.620 |
Why?
|
| Peptidyl-Dipeptidase A | 1 | 2020 | 361 | 0.610 |
Why?
|
| Quality of Life | 21 | 2024 | 13301 | 0.610 |
Why?
|
| Postoperative Complications | 8 | 2020 | 15684 | 0.600 |
Why?
|
| Platelet Glycoprotein GPIIb-IIIa Complex | 4 | 2017 | 638 | 0.600 |
Why?
|
| Osmolar Concentration | 2 | 2016 | 662 | 0.600 |
Why?
|
| Interdisciplinary Communication | 3 | 2020 | 934 | 0.590 |
Why?
|
| Evidence-Based Medicine | 5 | 2020 | 3697 | 0.590 |
Why?
|
| Secondary Prevention | 4 | 2019 | 1548 | 0.590 |
Why?
|
| Hyperlipidemias | 2 | 2014 | 782 | 0.590 |
Why?
|
| Drug Discovery | 2 | 2016 | 1056 | 0.590 |
Why?
|
| Funnel Chest | 1 | 2018 | 74 | 0.590 |
Why?
|
| Prosthesis Implantation | 3 | 2020 | 593 | 0.580 |
Why?
|
| Surgical Instruments | 1 | 2020 | 385 | 0.580 |
Why?
|
| Nurse Clinicians | 1 | 2017 | 30 | 0.580 |
Why?
|
| Acute Kidney Injury | 3 | 2024 | 1936 | 0.580 |
Why?
|
| Medicare Part C | 1 | 2022 | 322 | 0.570 |
Why?
|
| Prescription Drugs | 3 | 2021 | 630 | 0.570 |
Why?
|
| Clinical Trials, Phase III as Topic | 4 | 2018 | 859 | 0.560 |
Why?
|
| Health Expenditures | 6 | 2022 | 2359 | 0.560 |
Why?
|
| Retrospective Studies | 50 | 2024 | 80311 | 0.560 |
Why?
|
| Warfarin | 2 | 2017 | 1516 | 0.560 |
Why?
|
| Glucose | 12 | 2023 | 4361 | 0.560 |
Why?
|
| Echocardiography | 12 | 2024 | 4980 | 0.540 |
Why?
|
| Meta-Analysis as Topic | 2 | 2021 | 1375 | 0.540 |
Why?
|
| Hemoptysis | 1 | 2017 | 152 | 0.540 |
Why?
|
| Adenosine | 3 | 2017 | 833 | 0.540 |
Why?
|
| Tissue Donors | 4 | 2023 | 2314 | 0.540 |
Why?
|
| Prospective Studies | 39 | 2024 | 54265 | 0.540 |
Why?
|
| Aftercare | 7 | 2023 | 919 | 0.530 |
Why?
|
| Receptors, Purinergic P2Y1 | 1 | 2016 | 42 | 0.530 |
Why?
|
| Europe | 10 | 2024 | 3433 | 0.530 |
Why?
|
| Dinucleoside Phosphates | 1 | 2016 | 73 | 0.520 |
Why?
|
| Vaccination | 10 | 2024 | 3360 | 0.520 |
Why?
|
| Prediabetic State | 4 | 2022 | 550 | 0.520 |
Why?
|
| Pharmaceutical Preparations | 2 | 2021 | 1093 | 0.520 |
Why?
|
| Eye Diseases | 1 | 2021 | 651 | 0.520 |
Why?
|
| Incretins | 3 | 2021 | 103 | 0.510 |
Why?
|
| Heart Valve Diseases | 3 | 2012 | 1047 | 0.500 |
Why?
|
| Syncope | 1 | 2018 | 428 | 0.500 |
Why?
|
| Leg | 1 | 2020 | 1091 | 0.500 |
Why?
|
| Venous Thromboembolism | 4 | 2023 | 1866 | 0.500 |
Why?
|
| Financing, Organized | 1 | 2016 | 204 | 0.500 |
Why?
|
| Hemorrhage | 8 | 2021 | 3606 | 0.490 |
Why?
|
| Equipment Failure | 1 | 2017 | 577 | 0.490 |
Why?
|
| Morbidity | 6 | 2021 | 1765 | 0.490 |
Why?
|
| Fellowships and Scholarships | 3 | 2020 | 1118 | 0.480 |
Why?
|
| Periodicals as Topic | 6 | 2022 | 1470 | 0.480 |
Why?
|
| Physician Assistants | 1 | 2017 | 188 | 0.480 |
Why?
|
| Munchausen Syndrome | 1 | 2014 | 19 | 0.480 |
Why?
|
| Fibrinolytic Agents | 4 | 2024 | 2168 | 0.480 |
Why?
|
| Thrombectomy | 2 | 2020 | 708 | 0.470 |
Why?
|
| Models, Educational | 2 | 2014 | 372 | 0.470 |
Why?
|
| Furosemide | 4 | 2023 | 170 | 0.470 |
Why?
|
| Myocardial Ischemia | 3 | 2021 | 2161 | 0.470 |
Why?
|
| Dose-Response Relationship, Drug | 14 | 2024 | 10828 | 0.460 |
Why?
|
| Hepatic Encephalopathy | 1 | 2015 | 142 | 0.460 |
Why?
|
| Postoperative Hemorrhage | 1 | 2018 | 422 | 0.460 |
Why?
|
| Cohort Studies | 29 | 2023 | 41316 | 0.460 |
Why?
|
| Physicians | 3 | 2022 | 4590 | 0.460 |
Why?
|
| Emigrants and Immigrants | 1 | 2020 | 539 | 0.460 |
Why?
|
| Nurse Practitioners | 1 | 2017 | 268 | 0.460 |
Why?
|
| Sodium Chloride | 1 | 2016 | 596 | 0.450 |
Why?
|
| Enalapril | 5 | 2024 | 313 | 0.450 |
Why?
|
| Ocular Motility Disorders | 1 | 2015 | 143 | 0.450 |
Why?
|
| Diuresis | 1 | 2013 | 107 | 0.450 |
Why?
|
| Lymphocyte Count | 2 | 2013 | 780 | 0.450 |
Why?
|
| Clinical Trials, Phase II as Topic | 2 | 2014 | 629 | 0.450 |
Why?
|
| Heparin | 2 | 2020 | 1656 | 0.440 |
Why?
|
| Blood Loss, Surgical | 1 | 2018 | 657 | 0.440 |
Why?
|
| Sex Factors | 17 | 2024 | 10529 | 0.440 |
Why?
|
| Proportional Hazards Models | 20 | 2024 | 12531 | 0.440 |
Why?
|
| Thrombosis | 4 | 2020 | 3053 | 0.440 |
Why?
|
| Water-Electrolyte Imbalance | 1 | 2014 | 110 | 0.440 |
Why?
|
| Incidence | 19 | 2023 | 21379 | 0.440 |
Why?
|
| Coronary Occlusion | 1 | 2016 | 308 | 0.430 |
Why?
|
| Heart Neoplasms | 1 | 2016 | 361 | 0.430 |
Why?
|
| Biomedical Technology | 1 | 2015 | 211 | 0.430 |
Why?
|
| Monitoring, Physiologic | 3 | 2017 | 1784 | 0.430 |
Why?
|
| Bumetanide | 1 | 2013 | 96 | 0.430 |
Why?
|
| Mineralocorticoids | 2 | 2023 | 38 | 0.430 |
Why?
|
| Laryngeal Neoplasms | 1 | 2016 | 514 | 0.420 |
Why?
|
| Gastrointestinal Diseases | 2 | 2024 | 1188 | 0.420 |
Why?
|
| Medicine | 1 | 2021 | 943 | 0.420 |
Why?
|
| Cardiac Surgical Procedures | 3 | 2020 | 3618 | 0.420 |
Why?
|
| Length of Stay | 6 | 2021 | 6474 | 0.420 |
Why?
|
| Sodium-Glucose Transporter 2 | 3 | 2023 | 98 | 0.420 |
Why?
|
| Delivery of Health Care, Integrated | 1 | 2020 | 936 | 0.410 |
Why?
|
| Diabetes Complications | 1 | 2019 | 1342 | 0.410 |
Why?
|
| Age Distribution | 6 | 2021 | 2893 | 0.410 |
Why?
|
| Longevity | 1 | 2020 | 1050 | 0.410 |
Why?
|
| Obesity | 10 | 2024 | 12913 | 0.400 |
Why?
|
| Calcinosis | 3 | 2020 | 1478 | 0.400 |
Why?
|
| Survival Rate | 19 | 2021 | 12806 | 0.400 |
Why?
|
| Exercise Test | 2 | 2023 | 2125 | 0.400 |
Why?
|
| School Health Services | 1 | 2015 | 382 | 0.400 |
Why?
|
| Prevalence | 18 | 2024 | 15684 | 0.390 |
Why?
|
| Coronary Artery Bypass | 6 | 2021 | 2274 | 0.390 |
Why?
|
| Renal Dialysis | 2 | 2024 | 1802 | 0.390 |
Why?
|
| Disease Progression | 15 | 2024 | 13503 | 0.390 |
Why?
|
| Myocardium | 4 | 2020 | 4687 | 0.390 |
Why?
|
| Lung Transplantation | 1 | 2020 | 1304 | 0.370 |
Why?
|
| Safety | 1 | 2016 | 1149 | 0.370 |
Why?
|
| Heart Failure, Systolic | 2 | 2023 | 136 | 0.370 |
Why?
|
| Neoplasms | 7 | 2023 | 22066 | 0.370 |
Why?
|
| Drug Design | 2 | 2015 | 1062 | 0.360 |
Why?
|
| Athletes | 1 | 2018 | 1125 | 0.360 |
Why?
|
| Tissue and Organ Procurement | 1 | 2019 | 944 | 0.360 |
Why?
|
| Vasodilator Agents | 4 | 2023 | 977 | 0.360 |
Why?
|
| Diabetic Cardiomyopathies | 2 | 2021 | 96 | 0.350 |
Why?
|
| Magnesium | 1 | 2013 | 810 | 0.350 |
Why?
|
| American Heart Association | 4 | 2024 | 1082 | 0.350 |
Why?
|
| Government Programs | 2 | 2023 | 280 | 0.340 |
Why?
|
| Body Mass Index | 7 | 2022 | 12900 | 0.340 |
Why?
|
| Uric Acid | 2 | 2023 | 807 | 0.340 |
Why?
|
| Adult | 49 | 2024 | 219843 | 0.340 |
Why?
|
| Ischemic Attack, Transient | 3 | 2021 | 899 | 0.340 |
Why?
|
| Heart | 3 | 2022 | 4391 | 0.330 |
Why?
|
| Aortic Valve Stenosis | 3 | 2023 | 2066 | 0.330 |
Why?
|
| Mortality | 6 | 2021 | 2916 | 0.330 |
Why?
|
| Curriculum | 2 | 2022 | 3722 | 0.330 |
Why?
|
| Troponin I | 4 | 2024 | 634 | 0.330 |
Why?
|
| Cystatin C | 3 | 2023 | 270 | 0.330 |
Why?
|
| Ambulatory Care | 1 | 2020 | 2783 | 0.330 |
Why?
|
| Nutrition Surveys | 5 | 2023 | 1727 | 0.320 |
Why?
|
| Hemodynamics | 4 | 2015 | 4169 | 0.320 |
Why?
|
| Platelet Activation | 4 | 2015 | 661 | 0.320 |
Why?
|
| Pulmonary Artery | 1 | 2017 | 1919 | 0.320 |
Why?
|
| Health Promotion | 2 | 2023 | 2208 | 0.320 |
Why?
|
| Journal Impact Factor | 3 | 2020 | 156 | 0.310 |
Why?
|
| Education, Medical, Graduate | 2 | 2018 | 2359 | 0.310 |
Why?
|
| Salaries and Fringe Benefits | 2 | 2021 | 258 | 0.310 |
Why?
|
| Kaplan-Meier Estimate | 11 | 2024 | 6546 | 0.310 |
Why?
|
| Electrocardiography | 10 | 2020 | 6412 | 0.310 |
Why?
|
| Patient Care Management | 3 | 2021 | 303 | 0.310 |
Why?
|
| Creatinine | 8 | 2024 | 1907 | 0.310 |
Why?
|
| Drugs, Generic | 3 | 2023 | 448 | 0.310 |
Why?
|
| Telemedicine | 2 | 2023 | 3004 | 0.310 |
Why?
|
| Self-Injurious Behavior | 1 | 2014 | 559 | 0.300 |
Why?
|
| Tachycardia, Ventricular | 1 | 2016 | 1302 | 0.300 |
Why?
|
| Heart Arrest | 1 | 2018 | 1506 | 0.300 |
Why?
|
| Overweight | 3 | 2023 | 2421 | 0.290 |
Why?
|
| Authorship | 2 | 2020 | 281 | 0.290 |
Why?
|
| Peripheral Arterial Disease | 3 | 2024 | 1316 | 0.290 |
Why?
|
| Severity of Illness Index | 14 | 2021 | 15828 | 0.290 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 5 | 2023 | 3223 | 0.280 |
Why?
|
| Kansas | 2 | 2023 | 39 | 0.280 |
Why?
|
| Multicenter Studies as Topic | 5 | 2019 | 1723 | 0.280 |
Why?
|
| Polypharmacy | 3 | 2024 | 307 | 0.280 |
Why?
|
| Acute Disease | 10 | 2024 | 7268 | 0.270 |
Why?
|
| Quality Improvement | 2 | 2021 | 3840 | 0.270 |
Why?
|
| Chronic Disease | 12 | 2024 | 9287 | 0.270 |
Why?
|
| Intraoperative Period | 2 | 2017 | 516 | 0.260 |
Why?
|
| Electronic Health Records | 4 | 2023 | 4762 | 0.260 |
Why?
|
| Myocardial Revascularization | 4 | 2020 | 841 | 0.260 |
Why?
|
| Blood Vessel Prosthesis Implantation | 1 | 2015 | 1426 | 0.250 |
Why?
|
| Leukocytes | 1 | 2013 | 2030 | 0.250 |
Why?
|
| Coronary Angiography | 6 | 2021 | 4561 | 0.240 |
Why?
|
| Sodium Potassium Chloride Symporter Inhibitors | 2 | 2023 | 150 | 0.240 |
Why?
|
| Health Care Costs | 3 | 2024 | 3257 | 0.240 |
Why?
|
| Dyspnea | 4 | 2023 | 1352 | 0.240 |
Why?
|
| Injections, Intravenous | 2 | 2017 | 1388 | 0.240 |
Why?
|
| Sex Distribution | 5 | 2021 | 2295 | 0.230 |
Why?
|
| Product Surveillance, Postmarketing | 2 | 2020 | 450 | 0.230 |
Why?
|
| Potassium | 2 | 2021 | 1318 | 0.230 |
Why?
|
| Patient Care Team | 3 | 2023 | 2510 | 0.230 |
Why?
|
| Glucagon-Like Peptide 1 | 2 | 2023 | 366 | 0.230 |
Why?
|
| Particulate Matter | 1 | 2016 | 2558 | 0.230 |
Why?
|
| Physicians, Women | 2 | 2020 | 492 | 0.230 |
Why?
|
| Health Behavior | 1 | 2015 | 2621 | 0.230 |
Why?
|
| Thoracic Surgery | 2 | 2020 | 722 | 0.230 |
Why?
|
| Life Style | 1 | 2015 | 3888 | 0.230 |
Why?
|
| Veterans | 3 | 2022 | 2640 | 0.230 |
Why?
|
| Dihydropyridines | 1 | 2023 | 68 | 0.220 |
Why?
|
| Preoperative Care | 2 | 2012 | 2256 | 0.220 |
Why?
|
| Palliative Care | 1 | 2018 | 3607 | 0.220 |
Why?
|
| Age Factors | 12 | 2021 | 18416 | 0.220 |
Why?
|
| Lipids | 1 | 2014 | 3336 | 0.220 |
Why?
|
| Therapies, Investigational | 2 | 2014 | 111 | 0.220 |
Why?
|
| Freedom | 1 | 2023 | 70 | 0.220 |
Why?
|
| North America | 4 | 2024 | 1282 | 0.210 |
Why?
|
| Health Services Accessibility | 1 | 2020 | 5395 | 0.210 |
Why?
|
| Erythrocyte Indices | 1 | 2023 | 145 | 0.210 |
Why?
|
| Outpatients | 5 | 2024 | 1605 | 0.210 |
Why?
|
| Cross-Sectional Studies | 12 | 2023 | 25927 | 0.210 |
Why?
|
| Growth Differentiation Factor 15 | 3 | 2021 | 192 | 0.210 |
Why?
|
| Natriuretic Agents | 2 | 2019 | 57 | 0.210 |
Why?
|
| Fatal Outcome | 3 | 2017 | 1833 | 0.210 |
Why?
|
| Cost-Benefit Analysis | 5 | 2024 | 5508 | 0.200 |
Why?
|
| Publishing | 2 | 2020 | 837 | 0.200 |
Why?
|
| Prescriptions | 2 | 2023 | 388 | 0.200 |
Why?
|
| Head and Neck Neoplasms | 1 | 2016 | 2880 | 0.200 |
Why?
|
| Healthcare Disparities | 5 | 2022 | 3380 | 0.200 |
Why?
|
| Data Interpretation, Statistical | 3 | 2020 | 2696 | 0.200 |
Why?
|
| Decision Making | 3 | 2022 | 3924 | 0.200 |
Why?
|
| Infusions, Intravenous | 3 | 2017 | 2235 | 0.200 |
Why?
|
| Bibliometrics | 3 | 2020 | 351 | 0.200 |
Why?
|
| Hypertrophy, Left Ventricular | 4 | 2020 | 853 | 0.200 |
Why?
|
| Receptors, Mineralocorticoid | 1 | 2023 | 164 | 0.200 |
Why?
|
| Fibric Acids | 1 | 2021 | 29 | 0.200 |
Why?
|
| Atrial Function, Left | 2 | 2020 | 186 | 0.200 |
Why?
|
| Cooperative Behavior | 2 | 2020 | 1500 | 0.200 |
Why?
|
| Glucose Metabolism Disorders | 1 | 2021 | 52 | 0.190 |
Why?
|
| Models, Cardiovascular | 2 | 2024 | 973 | 0.190 |
Why?
|
| Italy | 3 | 2024 | 840 | 0.190 |
Why?
|
| Ventricular Remodeling | 3 | 2022 | 1259 | 0.190 |
Why?
|
| Vasopressins | 2 | 2012 | 355 | 0.190 |
Why?
|
| Insulin | 3 | 2021 | 6592 | 0.190 |
Why?
|
| Eligibility Determination | 2 | 2021 | 419 | 0.190 |
Why?
|
| Anemia | 3 | 2023 | 1511 | 0.190 |
Why?
|
| Denmark | 4 | 2024 | 759 | 0.190 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2016 | 4024 | 0.190 |
Why?
|
| Reimbursement, Incentive | 2 | 2019 | 543 | 0.190 |
Why?
|
| Fasting | 2 | 2018 | 1603 | 0.190 |
Why?
|
| Thromboembolism | 2 | 2019 | 1016 | 0.190 |
Why?
|
| National Library of Medicine (U.S.) | 1 | 2020 | 35 | 0.190 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2015 | 3967 | 0.180 |
Why?
|
| Enzyme Inhibitors | 3 | 2023 | 3726 | 0.180 |
Why?
|
| Niacin | 1 | 2021 | 119 | 0.180 |
Why?
|
| Chi-Square Distribution | 4 | 2017 | 3469 | 0.180 |
Why?
|
| Physical Examination | 3 | 2021 | 1244 | 0.180 |
Why?
|
| Enoxaparin | 1 | 2023 | 397 | 0.180 |
Why?
|
| Renal Artery | 1 | 2022 | 368 | 0.180 |
Why?
|
| Population Surveillance | 3 | 2021 | 2609 | 0.180 |
Why?
|
| Receptors, Angiotensin | 1 | 2020 | 141 | 0.180 |
Why?
|
| Quality of Health Care | 5 | 2020 | 4361 | 0.180 |
Why?
|
| Antineoplastic Agents | 3 | 2023 | 13629 | 0.180 |
Why?
|
| Logistic Models | 9 | 2023 | 13315 | 0.180 |
Why?
|
| Platelet Function Tests | 4 | 2016 | 303 | 0.180 |
Why?
|
| Delivery of Health Care | 2 | 2019 | 5324 | 0.170 |
Why?
|
| Predictive Value of Tests | 11 | 2021 | 15272 | 0.170 |
Why?
|
| Kidney Failure, Chronic | 2 | 2023 | 2469 | 0.170 |
Why?
|
| Monitoring, Ambulatory | 1 | 2023 | 353 | 0.170 |
Why?
|
| Medication Adherence | 4 | 2020 | 2163 | 0.170 |
Why?
|
| Anti-Arrhythmia Agents | 2 | 2022 | 784 | 0.170 |
Why?
|
| Orphan Drug Production | 1 | 2020 | 48 | 0.170 |
Why?
|
| Piperazines | 4 | 2015 | 2520 | 0.170 |
Why?
|
| Thiophenes | 2 | 2015 | 587 | 0.170 |
Why?
|
| Benzoxazoles | 1 | 2020 | 89 | 0.170 |
Why?
|
| Fatty Acids, Omega-3 | 2 | 2021 | 1387 | 0.170 |
Why?
|
| Product Labeling | 1 | 2020 | 77 | 0.170 |
Why?
|
| Edema, Cardiac | 1 | 2018 | 19 | 0.160 |
Why?
|
| Research Report | 2 | 2019 | 370 | 0.160 |
Why?
|
| Matched-Pair Analysis | 3 | 2019 | 284 | 0.160 |
Why?
|
| Cyclooxygenase Inhibitors | 2 | 2019 | 364 | 0.160 |
Why?
|
| Survival Analysis | 7 | 2019 | 10185 | 0.160 |
Why?
|
| Chloroquine | 1 | 2020 | 277 | 0.160 |
Why?
|
| Systole | 3 | 2020 | 947 | 0.160 |
Why?
|
| Exercise | 3 | 2021 | 5784 | 0.160 |
Why?
|
| Reimbursement Mechanisms | 2 | 2021 | 664 | 0.160 |
Why?
|
| Quality Indicators, Health Care | 3 | 2020 | 1822 | 0.160 |
Why?
|
| Women | 1 | 2020 | 224 | 0.160 |
Why?
|
| Heart Rate | 4 | 2023 | 4167 | 0.160 |
Why?
|
| Uracil | 1 | 2020 | 207 | 0.160 |
Why?
|
| Risk | 5 | 2021 | 9629 | 0.150 |
Why?
|
| Drug Resistance | 2 | 2019 | 1616 | 0.150 |
Why?
|
| Heparin, Low-Molecular-Weight | 1 | 2020 | 346 | 0.150 |
Why?
|
| Mitral Valve Prolapse | 1 | 2020 | 215 | 0.150 |
Why?
|
| Uncertainty | 1 | 2023 | 754 | 0.150 |
Why?
|
| Anti-Obesity Agents | 1 | 2021 | 229 | 0.150 |
Why?
|
| Drug Costs | 2 | 2023 | 1184 | 0.150 |
Why?
|
| Databases, Factual | 7 | 2021 | 8022 | 0.150 |
Why?
|
| Coronavirus | 1 | 2020 | 149 | 0.150 |
Why?
|
| Pyridones | 1 | 2023 | 788 | 0.150 |
Why?
|
| Guideline Adherence | 4 | 2024 | 2283 | 0.150 |
Why?
|
| Uremia | 1 | 2018 | 201 | 0.150 |
Why?
|
| Amyloidosis | 1 | 2024 | 818 | 0.150 |
Why?
|
| Health Care Rationing | 1 | 2021 | 435 | 0.150 |
Why?
|
| Advanced Practice Nursing | 1 | 2017 | 17 | 0.150 |
Why?
|
| Quality-Adjusted Life Years | 1 | 2024 | 1724 | 0.140 |
Why?
|
| Health Policy | 2 | 2021 | 2678 | 0.140 |
Why?
|
| Pericarditis | 1 | 2018 | 135 | 0.140 |
Why?
|
| Heart Injuries | 1 | 2019 | 208 | 0.140 |
Why?
|
| Hospitals, University | 1 | 2019 | 568 | 0.140 |
Why?
|
| Fee-for-Service Plans | 1 | 2022 | 705 | 0.140 |
Why?
|
| Young Adult | 12 | 2024 | 58673 | 0.140 |
Why?
|
| Organizational Innovation | 1 | 2020 | 536 | 0.140 |
Why?
|
| Health Services Misuse | 1 | 2019 | 245 | 0.140 |
Why?
|
| Emergencies | 2 | 2020 | 1217 | 0.140 |
Why?
|
| Chemoprevention | 1 | 2019 | 326 | 0.140 |
Why?
|
| Liver Diseases | 2 | 2018 | 1301 | 0.140 |
Why?
|
| Pilot Projects | 2 | 2021 | 8553 | 0.140 |
Why?
|
| Aldosterone | 1 | 2021 | 868 | 0.140 |
Why?
|
| Cost of Illness | 5 | 2021 | 1940 | 0.140 |
Why?
|
| Algorithms | 3 | 2024 | 13959 | 0.130 |
Why?
|
| Leukemia, Myelomonocytic, Chronic | 1 | 2017 | 93 | 0.130 |
Why?
|
| Cell Differentiation | 1 | 2013 | 11481 | 0.130 |
Why?
|
| Delayed-Action Preparations | 1 | 2020 | 961 | 0.130 |
Why?
|
| Hydroxychloroquine | 1 | 2020 | 428 | 0.130 |
Why?
|
| Catheterization, Swan-Ganz | 2 | 2014 | 87 | 0.130 |
Why?
|
| Immunoglobulin Fab Fragments | 1 | 2017 | 465 | 0.130 |
Why?
|
| Gout | 1 | 2023 | 619 | 0.130 |
Why?
|
| Regression Analysis | 2 | 2018 | 6361 | 0.130 |
Why?
|
| Odds Ratio | 4 | 2020 | 9714 | 0.130 |
Why?
|
| Demography | 1 | 2020 | 1650 | 0.130 |
Why?
|
| Endocrinology | 1 | 2022 | 442 | 0.130 |
Why?
|
| Journalism, Medical | 1 | 2016 | 73 | 0.130 |
Why?
|
| New Zealand | 1 | 2016 | 355 | 0.130 |
Why?
|
| Thailand | 1 | 2016 | 289 | 0.130 |
Why?
|
| Government Regulation | 2 | 2018 | 526 | 0.130 |
Why?
|
| Aortic Valve Insufficiency | 1 | 2020 | 584 | 0.130 |
Why?
|
| Biological Specimen Banks | 1 | 2021 | 776 | 0.130 |
Why?
|
| Death | 1 | 2020 | 678 | 0.130 |
Why?
|
| Program Development | 2 | 2018 | 1298 | 0.130 |
Why?
|
| Drug Tolerance | 1 | 2017 | 369 | 0.130 |
Why?
|
| Liver Cirrhosis, Alcoholic | 1 | 2015 | 64 | 0.130 |
Why?
|
| Muscular Diseases | 1 | 2019 | 552 | 0.120 |
Why?
|
| Models, Organizational | 1 | 2018 | 545 | 0.120 |
Why?
|
| Financing, Government | 1 | 2018 | 472 | 0.120 |
Why?
|
| European Union | 1 | 2016 | 157 | 0.120 |
Why?
|
| Intention to Treat Analysis | 1 | 2016 | 422 | 0.120 |
Why?
|
| Dyspepsia | 1 | 2016 | 118 | 0.120 |
Why?
|
| Osteoprotegerin | 1 | 2015 | 177 | 0.120 |
Why?
|
| Alkaline Phosphatase | 2 | 2015 | 865 | 0.120 |
Why?
|
| Angiography | 1 | 2020 | 1605 | 0.120 |
Why?
|
| Hypoglycemia | 1 | 2022 | 888 | 0.120 |
Why?
|
| Hydrazones | 2 | 2013 | 102 | 0.120 |
Why?
|
| Benzimidazoles | 1 | 2020 | 858 | 0.120 |
Why?
|
| P-Selectin | 4 | 2015 | 600 | 0.120 |
Why?
|
| Health Status Indicators | 1 | 2020 | 968 | 0.120 |
Why?
|
| Aspartate Aminotransferases | 2 | 2013 | 415 | 0.120 |
Why?
|
| Peptic Ulcer | 1 | 2016 | 219 | 0.120 |
Why?
|
| Patients | 1 | 2021 | 906 | 0.120 |
Why?
|
| Treatment Failure | 3 | 2016 | 2646 | 0.120 |
Why?
|
| Access to Information | 1 | 2017 | 320 | 0.120 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2018 | 675 | 0.120 |
Why?
|
| Face | 1 | 2020 | 1017 | 0.120 |
Why?
|
| Physical Fitness | 1 | 2018 | 732 | 0.120 |
Why?
|
| Intestinal Perforation | 1 | 2016 | 250 | 0.110 |
Why?
|
| Israel | 1 | 2016 | 722 | 0.110 |
Why?
|
| Vancomycin | 1 | 2017 | 503 | 0.110 |
Why?
|
| Peer Review | 1 | 2016 | 218 | 0.110 |
Why?
|
| Activities of Daily Living | 1 | 2023 | 2414 | 0.110 |
Why?
|
| Embolism, Air | 1 | 2014 | 110 | 0.110 |
Why?
|
| RANK Ligand | 1 | 2015 | 318 | 0.110 |
Why?
|
| Patient Protection and Affordable Care Act | 2 | 2020 | 1200 | 0.110 |
Why?
|
| Exercise Tolerance | 1 | 2019 | 827 | 0.110 |
Why?
|
| Osteopontin | 1 | 2015 | 303 | 0.110 |
Why?
|
| Body Water | 1 | 2015 | 335 | 0.110 |
Why?
|
| Monocytes | 2 | 2013 | 2574 | 0.110 |
Why?
|
| Chicago | 2 | 2012 | 244 | 0.110 |
Why?
|
| Adolescent | 9 | 2024 | 87749 | 0.110 |
Why?
|
| Alanine Transaminase | 2 | 2013 | 607 | 0.110 |
Why?
|
| Anticholesteremic Agents | 1 | 2021 | 988 | 0.110 |
Why?
|
| Blood Transfusion | 2 | 2018 | 1328 | 0.110 |
Why?
|
| DNA, Viral | 1 | 2020 | 2195 | 0.110 |
Why?
|
| Embolism | 1 | 2017 | 408 | 0.110 |
Why?
|
| Blood Cell Count | 1 | 2014 | 398 | 0.110 |
Why?
|
| Research Support as Topic | 1 | 2017 | 699 | 0.110 |
Why?
|
| Second Messenger Systems | 1 | 2013 | 202 | 0.110 |
Why?
|
| Arrhythmia, Sinus | 1 | 2012 | 48 | 0.110 |
Why?
|
| Endocarditis, Bacterial | 1 | 2017 | 445 | 0.110 |
Why?
|
| Cardiac Resynchronization Therapy | 2 | 2016 | 556 | 0.110 |
Why?
|
| Continuity of Patient Care | 1 | 2020 | 1067 | 0.110 |
Why?
|
| Xanthines | 1 | 2013 | 122 | 0.110 |
Why?
|
| Minority Groups | 1 | 2020 | 1199 | 0.110 |
Why?
|
| Graft Occlusion, Vascular | 1 | 2016 | 560 | 0.100 |
Why?
|
| Multivariate Analysis | 5 | 2020 | 12159 | 0.100 |
Why?
|
| Down-Regulation | 1 | 2020 | 2919 | 0.100 |
Why?
|
| Sample Size | 1 | 2016 | 840 | 0.100 |
Why?
|
| Drug Administration Schedule | 4 | 2019 | 4900 | 0.100 |
Why?
|
| Urban Population | 1 | 2021 | 2021 | 0.100 |
Why?
|
| Sensitivity and Specificity | 2 | 2021 | 14655 | 0.100 |
Why?
|
| Leukocyte Count | 2 | 2013 | 1600 | 0.100 |
Why?
|
| Social Class | 1 | 2021 | 2005 | 0.100 |
Why?
|
| Cyclic GMP | 1 | 2013 | 395 | 0.100 |
Why?
|
| Government | 2 | 2023 | 160 | 0.100 |
Why?
|
| Illinois | 1 | 2012 | 118 | 0.100 |
Why?
|
| Administration, Oral | 3 | 2019 | 4045 | 0.100 |
Why?
|
| Blood Urea Nitrogen | 2 | 2024 | 187 | 0.100 |
Why?
|
| Recurrence | 4 | 2024 | 8487 | 0.100 |
Why?
|
| Chemistry, Pharmaceutical | 1 | 2013 | 277 | 0.100 |
Why?
|
| Health Facilities | 1 | 2017 | 578 | 0.100 |
Why?
|
| Intestinal Obstruction | 1 | 2016 | 435 | 0.100 |
Why?
|
| Brazil | 1 | 2016 | 1214 | 0.100 |
Why?
|
| Sodium Channel Blockers | 1 | 2013 | 172 | 0.100 |
Why?
|
| Eye Movements | 1 | 2015 | 508 | 0.100 |
Why?
|
| Autonomic Nervous System | 1 | 2017 | 697 | 0.100 |
Why?
|
| Hematocrit | 1 | 2013 | 630 | 0.100 |
Why?
|
| Societies, Medical | 1 | 2024 | 3903 | 0.100 |
Why?
|
| Diagnostic Errors | 1 | 2019 | 1266 | 0.100 |
Why?
|
| Acetanilides | 1 | 2013 | 169 | 0.100 |
Why?
|
| Forecasting | 2 | 2018 | 2931 | 0.100 |
Why?
|
| Cell Size | 2 | 2010 | 623 | 0.100 |
Why?
|
| Bariatric Surgery | 1 | 2021 | 1006 | 0.090 |
Why?
|
| Extracorporeal Membrane Oxygenation | 2 | 2020 | 1456 | 0.090 |
Why?
|
| Piperidines | 1 | 2020 | 1650 | 0.090 |
Why?
|
| Immunity, Cellular | 1 | 2017 | 1558 | 0.090 |
Why?
|
| Sodium, Dietary | 1 | 2015 | 425 | 0.090 |
Why?
|
| Pyridazines | 1 | 2013 | 200 | 0.090 |
Why?
|
| Terminology as Topic | 1 | 2018 | 1534 | 0.090 |
Why?
|
| Drug Interactions | 1 | 2015 | 1426 | 0.090 |
Why?
|
| Health Surveys | 1 | 2021 | 4061 | 0.090 |
Why?
|
| Diabetic Angiopathies | 3 | 2021 | 822 | 0.090 |
Why?
|
| Comparative Effectiveness Research | 1 | 2016 | 718 | 0.090 |
Why?
|
| Coronary Stenosis | 2 | 2014 | 820 | 0.090 |
Why?
|
| Methicillin-Resistant Staphylococcus aureus | 1 | 2017 | 695 | 0.090 |
Why?
|
| Arachidonic Acid | 2 | 2010 | 434 | 0.090 |
Why?
|
| Colchicine | 2 | 2023 | 261 | 0.090 |
Why?
|
| Animals | 11 | 2022 | 167935 | 0.090 |
Why?
|
| Obesity, Morbid | 1 | 2021 | 1287 | 0.090 |
Why?
|
| Propensity Score | 3 | 2012 | 1921 | 0.090 |
Why?
|
| Electrophysiology | 1 | 2013 | 1265 | 0.090 |
Why?
|
| Blood Coagulation Disorders | 1 | 2013 | 349 | 0.090 |
Why?
|
| Biomedical Research | 2 | 2018 | 3421 | 0.090 |
Why?
|
| New York | 2 | 2023 | 874 | 0.090 |
Why?
|
| Rural Population | 1 | 2021 | 2267 | 0.090 |
Why?
|
| Protons | 1 | 2015 | 1113 | 0.090 |
Why?
|
| Cholesterol | 3 | 2021 | 2925 | 0.090 |
Why?
|
| Academic Medical Centers | 1 | 2020 | 2753 | 0.090 |
Why?
|
| Cardiopulmonary Resuscitation | 1 | 2018 | 1004 | 0.090 |
Why?
|
| Aortic Valve | 1 | 2020 | 1998 | 0.090 |
Why?
|
| Seasons | 1 | 2016 | 1523 | 0.090 |
Why?
|
| Depression | 2 | 2020 | 8034 | 0.090 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 2024 | 3450 | 0.080 |
Why?
|
| Head | 1 | 2015 | 921 | 0.080 |
Why?
|
| Myocarditis | 1 | 2017 | 766 | 0.080 |
Why?
|
| Longitudinal Studies | 3 | 2021 | 14481 | 0.080 |
Why?
|
| Pneumonia | 1 | 2021 | 2138 | 0.080 |
Why?
|
| Blood Proteins | 2 | 2020 | 1172 | 0.080 |
Why?
|
| Health Care Reform | 1 | 2018 | 1245 | 0.080 |
Why?
|
| Referral and Consultation | 2 | 2019 | 3598 | 0.080 |
Why?
|
| Thrombolytic Therapy | 1 | 2018 | 2109 | 0.080 |
Why?
|
| Hepatitis C | 1 | 2019 | 1578 | 0.080 |
Why?
|
| Eosinophils | 1 | 2013 | 946 | 0.080 |
Why?
|
| Poverty | 1 | 2020 | 2695 | 0.080 |
Why?
|
| Reproducibility of Results | 3 | 2022 | 20045 | 0.080 |
Why?
|
| Staphylococcal Infections | 1 | 2017 | 1405 | 0.080 |
Why?
|
| Organ Transplantation | 1 | 2018 | 1150 | 0.070 |
Why?
|
| Public Health | 1 | 2020 | 2655 | 0.070 |
Why?
|
| Self Efficacy | 2 | 2023 | 629 | 0.070 |
Why?
|
| Drug Substitution | 2 | 2021 | 296 | 0.070 |
Why?
|
| Arrhythmias, Cardiac | 1 | 2017 | 2253 | 0.070 |
Why?
|
| Equipment Design | 1 | 2015 | 3521 | 0.070 |
Why?
|
| Inflammation Mediators | 1 | 2015 | 1882 | 0.070 |
Why?
|
| Case-Control Studies | 4 | 2019 | 22040 | 0.070 |
Why?
|
| Phosphodiesterase Inhibitors | 1 | 2007 | 214 | 0.070 |
Why?
|
| Triglycerides | 2 | 2012 | 2476 | 0.070 |
Why?
|
| Mast Cells | 1 | 2013 | 1428 | 0.070 |
Why?
|
| Sweden | 2 | 2021 | 1381 | 0.070 |
Why?
|
| Albumins | 2 | 2023 | 577 | 0.070 |
Why?
|
| Stomach Neoplasms | 1 | 2016 | 1423 | 0.070 |
Why?
|
| Statistics as Topic | 3 | 2021 | 2363 | 0.070 |
Why?
|
| Protein Precursors | 2 | 2020 | 1135 | 0.060 |
Why?
|
| Disease-Free Survival | 2 | 2012 | 6830 | 0.060 |
Why?
|
| Sodium-Glucose Transport Proteins | 1 | 2024 | 13 | 0.060 |
Why?
|
| Phenotype | 3 | 2021 | 16543 | 0.060 |
Why?
|
| Patient Education as Topic | 1 | 2014 | 2311 | 0.060 |
Why?
|
| Hospital Costs | 2 | 2021 | 978 | 0.060 |
Why?
|
| Echocardiography, Doppler | 2 | 2019 | 900 | 0.060 |
Why?
|
| Health Status Disparities | 3 | 2021 | 1820 | 0.060 |
Why?
|
| Plaque, Atherosclerotic | 1 | 2015 | 1520 | 0.060 |
Why?
|
| Diagnostic Imaging | 1 | 2018 | 3526 | 0.060 |
Why?
|
| Hypovolemia | 1 | 2023 | 48 | 0.050 |
Why?
|
| Latin America | 1 | 2024 | 405 | 0.050 |
Why?
|
| Caffeine | 1 | 2007 | 701 | 0.050 |
Why?
|
| Coronary Disease | 2 | 2012 | 5993 | 0.050 |
Why?
|
| Catheter Ablation | 2 | 2016 | 2755 | 0.050 |
Why?
|
| Primary Prevention | 2 | 2021 | 1207 | 0.050 |
Why?
|
| Early Diagnosis | 2 | 2023 | 1181 | 0.050 |
Why?
|
| Growth Differentiation Factors | 1 | 2023 | 99 | 0.050 |
Why?
|
| Sympathectomy | 1 | 2022 | 90 | 0.050 |
Why?
|
| Molecular Targeted Therapy | 1 | 2013 | 2805 | 0.050 |
Why?
|
| Combined Modality Therapy | 3 | 2020 | 8551 | 0.050 |
Why?
|
| Lipid Regulating Agents | 1 | 2021 | 28 | 0.050 |
Why?
|
| Substance-Related Disorders | 1 | 2018 | 4370 | 0.050 |
Why?
|
| Electronics | 1 | 2023 | 317 | 0.050 |
Why?
|
| Massachusetts | 3 | 2019 | 8805 | 0.050 |
Why?
|
| Retreatment | 2 | 2014 | 600 | 0.050 |
Why?
|
| Denervation | 1 | 2022 | 277 | 0.050 |
Why?
|
| Asymptomatic Diseases | 1 | 2024 | 582 | 0.050 |
Why?
|
| Health Care Coalitions | 1 | 2021 | 36 | 0.050 |
Why?
|
| Kidney Function Tests | 2 | 2013 | 680 | 0.050 |
Why?
|
| Up-Regulation | 2 | 2021 | 4127 | 0.050 |
Why?
|
| Endothelium, Vascular | 1 | 2013 | 4437 | 0.050 |
Why?
|
| Pyridines | 1 | 2013 | 2877 | 0.050 |
Why?
|
| Pain | 1 | 2016 | 5066 | 0.050 |
Why?
|
| Internationality | 2 | 2019 | 1005 | 0.050 |
Why?
|
| Michigan | 1 | 2021 | 342 | 0.050 |
Why?
|
| Esters | 1 | 2021 | 211 | 0.050 |
Why?
|
| Markov Chains | 1 | 2024 | 972 | 0.040 |
Why?
|
| India | 3 | 2019 | 2346 | 0.040 |
Why?
|
| Osteoarthritis | 1 | 2008 | 1055 | 0.040 |
Why?
|
| Calcium Channel Blockers | 1 | 2023 | 694 | 0.040 |
Why?
|
| Medication Therapy Management | 1 | 2021 | 132 | 0.040 |
Why?
|
| Sulfhydryl Compounds | 1 | 2021 | 299 | 0.040 |
Why?
|
| Pericardiocentesis | 1 | 2020 | 79 | 0.040 |
Why?
|
| Receptors, Chemokine | 1 | 2023 | 654 | 0.040 |
Why?
|
| Therapeutic Equivalency | 1 | 2020 | 136 | 0.040 |
Why?
|
| Emergency Service, Hospital | 1 | 2019 | 7809 | 0.040 |
Why?
|
| Thromboxane B2 | 2 | 2010 | 147 | 0.040 |
Why?
|
| Atrial Natriuretic Factor | 1 | 2020 | 350 | 0.040 |
Why?
|
| Hemodilution | 1 | 2019 | 121 | 0.040 |
Why?
|
| T-Lymphocytes | 1 | 2017 | 10183 | 0.040 |
Why?
|
| Heart Function Tests | 1 | 2020 | 319 | 0.040 |
Why?
|
| Catheters | 1 | 2022 | 426 | 0.040 |
Why?
|
| Isosorbide Dinitrate | 1 | 2019 | 37 | 0.040 |
Why?
|
| Intercellular Adhesion Molecule-1 | 1 | 2023 | 1128 | 0.040 |
Why?
|
| Breast Neoplasms | 2 | 2018 | 21065 | 0.040 |
Why?
|
| Ventricular Function, Right | 1 | 2023 | 610 | 0.040 |
Why?
|
| Intensive Care Units | 1 | 2012 | 3737 | 0.040 |
Why?
|
| Single-Blind Method | 1 | 2022 | 1577 | 0.040 |
Why?
|
| Accreditation | 1 | 2022 | 477 | 0.040 |
Why?
|
| Anti-Bacterial Agents | 1 | 2017 | 7398 | 0.040 |
Why?
|
| Adenocarcinoma | 1 | 2016 | 6310 | 0.040 |
Why?
|
| North Carolina | 1 | 2019 | 325 | 0.040 |
Why?
|
| Adenosine Diphosphate | 2 | 2010 | 429 | 0.040 |
Why?
|
| Sus scrofa | 1 | 2020 | 432 | 0.040 |
Why?
|
| Cross-Over Studies | 2 | 2019 | 2061 | 0.040 |
Why?
|
| Galectin 3 | 1 | 2020 | 240 | 0.040 |
Why?
|
| Peripheral Vascular Diseases | 1 | 2021 | 516 | 0.040 |
Why?
|
| Sympathetic Nervous System | 1 | 2020 | 519 | 0.040 |
Why?
|
| Linear Models | 2 | 2018 | 5877 | 0.040 |
Why?
|
| Clinical Protocols | 2 | 2014 | 1439 | 0.040 |
Why?
|
| Insurance, Health | 2 | 2021 | 2500 | 0.040 |
Why?
|
| Genetic Variation | 2 | 2023 | 6540 | 0.040 |
Why?
|
| Galectins | 1 | 2020 | 282 | 0.040 |
Why?
|
| Drug Dosage Calculations | 1 | 2017 | 118 | 0.040 |
Why?
|
| Procollagen | 1 | 2017 | 188 | 0.030 |
Why?
|
| Prejudice | 1 | 2021 | 563 | 0.030 |
Why?
|
| Poisoning | 1 | 2018 | 252 | 0.030 |
Why?
|
| Oxygen Consumption | 1 | 2023 | 1840 | 0.030 |
Why?
|
| ROC Curve | 2 | 2015 | 3570 | 0.030 |
Why?
|
| Membrane Glycoproteins | 1 | 2007 | 3731 | 0.030 |
Why?
|
| Lipoprotein(a) | 1 | 2001 | 499 | 0.030 |
Why?
|
| Patient Admission | 2 | 2014 | 1384 | 0.030 |
Why?
|
| Hospitals, Teaching | 1 | 2021 | 1166 | 0.030 |
Why?
|
| Socioeconomic Factors | 2 | 2020 | 7802 | 0.030 |
Why?
|
| Receptor Activator of Nuclear Factor-kappa B | 1 | 2015 | 77 | 0.030 |
Why?
|
| Serine Endopeptidases | 1 | 2020 | 1021 | 0.030 |
Why?
|
| Nursing Homes | 1 | 2023 | 1076 | 0.030 |
Why?
|
| Placebos | 1 | 2019 | 1672 | 0.030 |
Why?
|
| Medically Uninsured | 1 | 2020 | 843 | 0.030 |
Why?
|
| Platelet Count | 2 | 2008 | 777 | 0.030 |
Why?
|
| Emergency Treatment | 1 | 2019 | 498 | 0.030 |
Why?
|
| Chemokine CCL5 | 1 | 2015 | 214 | 0.030 |
Why?
|
| Bayes Theorem | 1 | 2023 | 2326 | 0.030 |
Why?
|
| Brain Death | 1 | 2018 | 356 | 0.030 |
Why?
|
| Glucose Tolerance Test | 1 | 2018 | 1174 | 0.030 |
Why?
|
| Angina, Unstable | 1 | 2019 | 926 | 0.030 |
Why?
|
| Models, Economic | 1 | 2018 | 719 | 0.030 |
Why?
|
| Cholesterol, LDL | 2 | 2021 | 2422 | 0.030 |
Why?
|
| Pacemaker, Artificial | 1 | 2020 | 815 | 0.030 |
Why?
|
| Heart Septal Defects, Ventricular | 1 | 2017 | 491 | 0.030 |
Why?
|
| Nicaragua | 1 | 2013 | 29 | 0.030 |
Why?
|
| Cluster Analysis | 1 | 2021 | 2698 | 0.030 |
Why?
|
| Hypokalemia | 1 | 2015 | 153 | 0.030 |
Why?
|
| Drug Monitoring | 1 | 2020 | 966 | 0.030 |
Why?
|
| Glucose Intolerance | 1 | 2018 | 579 | 0.030 |
Why?
|
| China | 1 | 2020 | 2348 | 0.030 |
Why?
|
| Rome | 1 | 2013 | 28 | 0.030 |
Why?
|
| Chest Pain | 1 | 2020 | 1106 | 0.030 |
Why?
|
| Dyslipidemias | 1 | 2021 | 895 | 0.030 |
Why?
|
| Drug Industry | 1 | 2020 | 789 | 0.030 |
Why?
|
| After-Hours Care | 1 | 2014 | 101 | 0.030 |
Why?
|
| Europe, Eastern | 1 | 2012 | 72 | 0.030 |
Why?
|
| Blood Coagulation | 1 | 2019 | 1156 | 0.030 |
Why?
|
| Psychometrics | 1 | 2022 | 3049 | 0.030 |
Why?
|
| Vitamins | 1 | 2021 | 1635 | 0.030 |
Why?
|
| Hemostasis, Surgical | 1 | 2013 | 129 | 0.030 |
Why?
|
| Retroperitoneal Space | 1 | 2013 | 173 | 0.030 |
Why?
|
| South America | 1 | 2012 | 181 | 0.030 |
Why?
|
| Receptors, Vasopressin | 1 | 2012 | 106 | 0.030 |
Why?
|
| Prosthesis Design | 1 | 2019 | 2127 | 0.030 |
Why?
|
| Epidemics | 1 | 2018 | 513 | 0.030 |
Why?
|
| Syndrome | 1 | 2018 | 3278 | 0.030 |
Why?
|
| Asia | 1 | 2014 | 618 | 0.030 |
Why?
|
| Sex Characteristics | 1 | 2022 | 2627 | 0.030 |
Why?
|
| Hepacivirus | 1 | 2019 | 1333 | 0.030 |
Why?
|
| Magnetic Resonance Imaging, Cine | 1 | 2019 | 1038 | 0.020 |
Why?
|
| Antibiotic Prophylaxis | 1 | 2017 | 642 | 0.020 |
Why?
|
| Patient-Centered Care | 1 | 2021 | 1416 | 0.020 |
Why?
|
| Patient Participation | 1 | 2020 | 1437 | 0.020 |
Why?
|
| Dopamine | 1 | 2018 | 1583 | 0.020 |
Why?
|
| Editorial Policies | 1 | 2016 | 457 | 0.020 |
Why?
|
| Mexico | 1 | 2013 | 760 | 0.020 |
Why?
|
| Hyponatremia | 1 | 2014 | 281 | 0.020 |
Why?
|
| Carotid Arteries | 1 | 2015 | 951 | 0.020 |
Why?
|
| Liver Cirrhosis | 1 | 2021 | 1926 | 0.020 |
Why?
|
| Area Under Curve | 1 | 2015 | 1635 | 0.020 |
Why?
|
| Acid Phosphatase | 1 | 2010 | 139 | 0.020 |
Why?
|
| Glycemic Index | 1 | 2013 | 396 | 0.020 |
Why?
|
| Radiography, Thoracic | 1 | 2017 | 1295 | 0.020 |
Why?
|
| Program Evaluation | 1 | 2019 | 2494 | 0.020 |
Why?
|
| Heart Atria | 1 | 2016 | 1344 | 0.020 |
Why?
|
| Liver Function Tests | 1 | 2012 | 524 | 0.020 |
Why?
|
| Flow Cytometry | 2 | 2013 | 5873 | 0.020 |
Why?
|
| Critical Illness | 1 | 2023 | 2710 | 0.020 |
Why?
|
| Endarterectomy, Carotid | 1 | 2015 | 560 | 0.020 |
Why?
|
| Radiography | 2 | 2013 | 6965 | 0.020 |
Why?
|
| Lung Diseases | 1 | 2020 | 1915 | 0.020 |
Why?
|
| Fever | 1 | 2017 | 1618 | 0.020 |
Why?
|
| Thrombocytopenia | 1 | 2017 | 1174 | 0.020 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2016 | 36230 | 0.020 |
Why?
|
| Staphylococcus aureus | 1 | 2017 | 1462 | 0.020 |
Why?
|
| Epidemiologic Methods | 1 | 2013 | 1344 | 0.020 |
Why?
|
| Receptors, Thromboxane | 1 | 2008 | 30 | 0.020 |
Why?
|
| Dietary Supplements | 1 | 2021 | 3389 | 0.020 |
Why?
|
| Cyclooxygenase 1 | 1 | 2008 | 98 | 0.020 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2022 | 3159 | 0.020 |
Why?
|
| Evidence-Based Practice | 1 | 2012 | 495 | 0.020 |
Why?
|
| Ethics, Medical | 1 | 2013 | 787 | 0.020 |
Why?
|
| Hand Joints | 1 | 2008 | 58 | 0.020 |
Why?
|
| Congresses as Topic | 1 | 2013 | 804 | 0.020 |
Why?
|
| Life Expectancy | 1 | 2015 | 1249 | 0.020 |
Why?
|
| Coronary Circulation | 1 | 2014 | 1578 | 0.020 |
Why?
|
| Vitamin D | 1 | 2021 | 3293 | 0.020 |
Why?
|
| Insurance Coverage | 1 | 2018 | 1939 | 0.020 |
Why?
|
| Interleukin-6 | 1 | 2017 | 3207 | 0.020 |
Why?
|
| Fibrinogen | 1 | 2010 | 887 | 0.020 |
Why?
|
| Receptor, Adenosine A2A | 1 | 2007 | 128 | 0.020 |
Why?
|
| Receptors, Thrombin | 1 | 2007 | 132 | 0.020 |
Why?
|
| von Willebrand Factor | 1 | 2010 | 673 | 0.020 |
Why?
|
| Protein Array Analysis | 1 | 2008 | 401 | 0.020 |
Why?
|
| Confidence Intervals | 1 | 2012 | 2932 | 0.020 |
Why?
|
| Texas | 1 | 2007 | 401 | 0.020 |
Why?
|
| Cells, Cultured | 2 | 2013 | 18968 | 0.020 |
Why?
|
| Boston | 1 | 2019 | 9283 | 0.020 |
Why?
|
| Brain Ischemia | 1 | 2019 | 3128 | 0.020 |
Why?
|
| Isoenzymes | 1 | 2010 | 1690 | 0.020 |
Why?
|
| Recovery of Function | 1 | 2016 | 2983 | 0.020 |
Why?
|
| Biopsy | 1 | 2017 | 6775 | 0.020 |
Why?
|
| Models, Biological | 1 | 2020 | 9468 | 0.010 |
Why?
|
| Nitric Oxide | 1 | 2013 | 2140 | 0.010 |
Why?
|
| Smoking | 1 | 2021 | 9070 | 0.010 |
Why?
|
| C-Reactive Protein | 1 | 2015 | 3822 | 0.010 |
Why?
|
| Drug Synergism | 1 | 2007 | 1755 | 0.010 |
Why?
|
| Analysis of Variance | 1 | 2012 | 6242 | 0.010 |
Why?
|
| Mass Screening | 1 | 2019 | 5422 | 0.010 |
Why?
|
| Reference Values | 1 | 2008 | 4920 | 0.010 |
Why?
|
| Apolipoproteins A | 1 | 2001 | 95 | 0.010 |
Why?
|
| Apolipoprotein B-100 | 1 | 2001 | 155 | 0.010 |
Why?
|
| Students, Medical | 1 | 2013 | 1926 | 0.010 |
Why?
|
| Collagen | 1 | 2008 | 2635 | 0.010 |
Why?
|
| Apolipoproteins B | 1 | 2001 | 388 | 0.010 |
Why?
|
| Lung | 1 | 2017 | 9988 | 0.010 |
Why?
|
| Osteoarthritis, Knee | 1 | 2008 | 1234 | 0.010 |
Why?
|
| Immunoblotting | 1 | 2001 | 1649 | 0.010 |
Why?
|
| Apoptosis | 1 | 2013 | 9497 | 0.010 |
Why?
|
| Protein Isoforms | 1 | 2001 | 1697 | 0.010 |
Why?
|
| Cholesterol, HDL | 1 | 2001 | 1817 | 0.010 |
Why?
|
| Child | 1 | 2019 | 79759 | 0.010 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2001 | 17766 | 0.000 |
Why?
|